SION — Sionna Therapeutics Share Price
0.000.00%
Last trade - 00:00- $599.21m
- $450.72m
- 30
- 22
- 14
- 10
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.59 | ||
| Price to Tang. Book | 3.59 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -40.24% | ||
| Return on Equity | -61.18% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Sionna Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on researching and developing novel medicines for cystic fibrosis. It is advancing a pipeline of small molecules engineered to correct the defects caused by the F508del genetic mutation, which resides in nucleotide-binding domain 1 (NBD1). It is conducting ongoing Phase I trials of its two highly potent NBD1 stabilizers, SION-719 and SION-451, evaluating the safety, tolerability and pharmacokinetic (PK) profile of single and multiple ascending doses in healthy subjects. It is also developing a portfolio of cystic fibrosis transmembrane conductance regulator (CFTR) modulators designed to work synergistically with its NBD1 stabilizers to improve CFTR function. Its portfolio also includes Galicaftor (SION-2222) and SION-2851, which are TMD1-directed CFTR correctors; SION-109, an ICL4-directed CFTR corrector, and Navocaftor (SION-3067), is a clinical-stage potentiator of CFTR gating activity.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- August 21st, 2019
- Public Since
- February 7th, 2025
- No. of Shareholders
- 39
- No. of Employees
- 41
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 44,124,394
- Address
- 21 Hickory Drive, Suite 500, WALTHAM, 02451
- Web
- https://www.sionnatx.com/
- Phone
- +1 6178192020
- Auditors
- Deloitte & Touche LLP
Upcoming Events for SION
Q1 2025 Sionna Therapeutics Inc Earnings Release
Sionna Therapeutics Inc Annual Shareholders Meeting
Q2 2025 Sionna Therapeutics Inc Earnings Release
Similar to SION
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
ABPRO Holdings
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
FAQ
What is the Sionna Therapeutics share price?
As of Today at 23:17 UTC, shares in Sionna Therapeutics are trading at $13.58. This share price information is delayed by 15 minutes.
How has the Sionna Therapeutics share price performed this year?
Shares in Sionna Therapeutics last closed at $13.58 and the price had moved by over the past 365 days. In terms of relative price strength the Sionna Therapeutics share price has matched the S&P500 Index by over the past year.
What are the analyst and broker recommendations for Sionna Therapeutics?
The overall consensus recommendation for Sionna Therapeutics is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Sionna Therapeutics dividend yield?
Sionna Therapeutics does not currently pay a dividend.
Does Sionna Therapeutics pay a dividend?
Sionna Therapeutics does not currently pay a dividend.
When does Sionna Therapeutics next pay dividends?
Sionna Therapeutics does not currently pay a dividend.
How do I buy Sionna Therapeutics shares?
To buy shares in Sionna Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Sionna Therapeutics?
As of the previous close price of $13.58, shares in Sionna Therapeutics had a market capitalisation of $599.21m.
Where are Sionna Therapeutics shares listed?
Here are the trading details for Sionna Therapeutics:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: SION
What kind of share is Sionna Therapeutics?
Based on an overall assessment of its quality, value and momentum Sionna Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Sionna Therapeutics share price forecast for 2025?
The analyst consensus target price for shares in Sionna Therapeutics is $38.50. That is 183.51% above the last closing price of $13.58.
Analysts covering Sionna Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$2.20 for the next financial year.
Find out moreWhat is the trend in the Sionna Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Sionna Therapeutics. Over the past six months, its share price has matched the S&P500 Index by .
As of the last closing price of $13.58, shares in Sionna Therapeutics were trading -4.39% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Sionna Therapeutics PE Ratio?
The Sionna Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $13.58.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Sionna Therapeutics?
We do not have data on Sionna Therapeutics' directors